Trio Petroleum Corp

(c) Insider Trading Arrangements

As previously reported on the Company’s Quarterly Report on Form 10-Q for the period ended January 31, 2025, on January 22, 2025, Robin Ross, the Chief Executive Officer and Director of the Company, entered into a 10b5-1 sales plan (the “Ross January 2025 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, which Ross January 2025 10b5-1 Sales Plan provided for the sale of up to 150,000 shares of common stock and was set to remain in effect until the earlier of (1) July 22, 2026; or (2) the date on which an aggregate of 150,000 shares of common stock have been sold under the Ross 10b5-1 Sales Plan. On December 4, 2024, the Ross January 2025 10b5-1 Sales Plan was terminated.

As of the date of termination, none of the shares were sold and no other adjustments were made to the Ross January 2025 10b5-1 Sales Plan during the quarterly period prior to termination.

On September 17, 2025, Robin Ross, Chief Executive Officer and a Director of the Company, entered into a 10b5-1 sales plan (the “Ross 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Ross 10b5-1 Sales Plan provides for the sale of up to 150,000 shares of common stock and will remain in effect until the earlier of (1) August 17, 2026; or (2) the date on which an aggregate of 150,000 shares of common stock have been sold under the Ross 10b5-1 Sales Plan. As of the date of this Annual Report, 37,500 of the shares were sold and no other adjustments were made to the plan during the period covered by this Annual Report.

On October 3, 2025, Thomas J. Pernice, a Director of the Company, entered into a 10b5-1 sales plan (the “Pernice 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Pernice 10b5-1 Sales Plan provides for the sale of up to 250,000 shares of common stock and will remain in effect until the earlier of (1) October 10, 2026; or (2) the date on which an aggregate of 250,000 shares of common stock have been sold under the Pernice 10b5-1 Sales Plan. As of the date of this Annual Report, 25,000 of the shares were sold and no other adjustments were made to the plan during the period covered by this Annual Report.

On October 20, 2025, John W. Randall, a Director of the Company, entered into a 10b5-1 sales plan (the “Randall 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Randall 10b5-1 Sales Plan provides for the sale of up to 50,000 shares of common stock and will remain in effect until the earlier of (1) July 31, 2026; or (2) the date on which an aggregate of 50,000 shares of common stock have been sold under the Randall 10b5-1 Sales Plan. As of the date of this Annual Report, none of the shares were sold and no other adjustments were made to the plan during the period covered by this Annual Report; provided, however, that the Randall 10b5-1 Sales Plan provides for the first sale of 20,000 shares of common stock on February 1, 2026.

No other directors or executive officers of the Company adopted, modified orterminated any contract, instruction or written plan for the purchase or sale of the Company’s securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5 trading arrangement, (as defined in Item 408(c) of Regulation S-K) during the fiscal quarter ended October 31, 2025.